Acemannan: What New Research Shows About Aloe Vera's Active Molecule
Acemannan: What New Research Shows About Aloe Vera's Active Molecule
Aloe vera shows up everywhere in skincare: on packaging, in marketing copy, as a promise of calm and hydration. Most articles about the ingredient stop at surface-level claims without explaining what actually happens at the cellular level. There's a reason for that — this kind of research is relatively new, and it concerns one specific molecule in aloe vera, not the plant as a whole.
That molecule is called acemannan, and a study published in Scientific Reports in March 2025 shows, for the first time, exactly how it affects human skin cells. This article walks through what the study actually shows, what it doesn't show, and why it helps explain why SKINØ has formulated its range with organic aloe vera as the active base instead of water.
What Is Acemannan?
Acemannan is a β-(1,4)-acetylated mannan — a polysaccharide, meaning a long chain of sugar molecules — and one of the principal bioactive components in aloe vera gel. It's not the same thing as "aloe vera" as a whole; aloe vera contains dozens of different substances, and acemannan is one of the most studied and most extensively documented.
Acemannan has previously been linked to wound healing, immunomodulatory effects and antimicrobial activity across various research contexts. What was missing until recently was a direct, mechanistic explanation of how acemannan actually affects the skin's own cells — the keratinocytes, the cells that make up the bulk of the skin's outermost layer and that are decisive for the skin barrier's function.
New Research in 2025: How Acemannan Affects Skin Cells
The Study's Design
The researchers, based at institutions including National Taiwan University and National Taiwan University Hospital, used HaCaT cells — a well-established, spontaneously transformed keratinocyte cell line widely used in skin research — as a model to investigate how acemannan affects the cells' growth, movement and maturation. It's important to be clear about what that means: this is a cell-culture study, not a clinical test on a finished cosmetic product or on living skin. That kind of basic research is nonetheless central, since it shows the underlying biological mechanism rather than just an observed end result.
What the Researchers Actually Found
The study showed that acemannan increased keratinocyte cell growth in a concentration-dependent manner, without being cytotoxic at the concentrations tested (up to 3 mg/ml). The cells took up more BrdU, a marker showing that cells are actively dividing and building new DNA, confirming that acemannan stimulates cell proliferation rather than simply keeping the cells alive.
In a wound-healing model — where the researchers created a small gap between cell layers and measured how quickly the cells migrated to close it — cells treated with acemannan showed clearly faster migration than untreated cells. That's directly relevant to the skin's ability to heal and renew itself.
Acemannan also affected the cells' maturation process (differentiation): the expression of involucrin, loricrin and transglutaminase 1 — proteins central to building a functioning, protective skin barrier — increased measurably after treatment.
The Mechanism Behind the Effect
What makes the study particularly interesting is that the researchers also mapped the pathway behind it. Acemannan activated EGFR (epidermal growth factor receptor) and PKC (protein kinase C), two signalling pathways known to govern keratinocyte growth, movement and maturation. When the researchers blocked EGFR with an inhibitor (osimertinib), acemannan's effect on both cell growth and migration was cancelled out, confirming that EGFR activation is a necessary part of the mechanism. The effect could be reproduced in primary human keratinocytes (NHEK), not just in the cell line, which strengthens its relevance further.
In short: acemannan sends the same type of growth signal to skin cells that the body's own growth factors do, via an identified and verified molecular pathway.
Why Topical Use Differs from Oral Supplements
Here it's worth being honest about something often overlooked in skincare marketing: not all aloe vera research points in the same direction, and the route into the body matters a great deal.
A systematic literature review and meta-analysis published in 2025 in Studies in Multidisciplinary Medical Research examined four randomised, placebo-controlled trials (284 participants total) on oral aloe vera supplements (aloe sterol capsules, tablets and powder in yoghurt) and their effect on skin ageing. The result was clear: compared with placebo, oral aloe vera supplementation showed no significant effect on skin moisture, transepidermal water loss, elasticity or collagen score after 4, 8 or 12 weeks. A marginal improvement in wrinkle width was seen in participants aged 40 and older, but this was based on a single study and was assessed as low-certainty evidence.
The authors' conclusion was direct: "current evidence does not justify recommending oral Aloe vera as a standalone intervention for skin aging."
This isn't a contradiction of the acemannan study — it's an important distinction. A supplement that's swallowed has to pass through the digestive system, be absorbed into the blood and reach the skin in a biologically active form in sufficient quantity — a journey where a great deal can be lost along the way. A topical formulation places the active ingredient in direct contact with the very cells — the keratinocytes — that the acemannan study showed respond to the molecule. That's the same logic that explains why the new research is relevant specifically to skincare products applied to the skin, not to dietary supplements.
SKINØ's Formulation Choice: Aloe Vera as the Active Base, Not Just Marketing
It's against that background that SKINØ's formulation philosophy becomes more comprehensible than a simple marketing claim. Instead of using water as the base and adding aloe vera as a minor ingredient further down the list, organic Aloe Barbadensis Leaf Juice is the first ingredient on the INCI list for several of the range's core products: SKINØ Peptide Anti-Aging Serum, SKINØ Hydrating Serum, SKINØ Anti-Age Day Cream, SKINØ Moisturising Day Cream and SKINØ Micellar Water.
It should be stated clearly: SKINØ's products have not been clinically tested in the specific study described above, and a finished cosmetic formulation is not the same thing as purified acemannan in a lab setting. What the research provides is a mechanistic explanation for why aloe vera as a carrier liquid is a meaningful formulation choice rather than an empty marketing word — the leaf gel naturally contains acemannan among its bioactive components, and the new research builds a credible biological foundation for why an aloe-vera-based formula can do more than simply dissolve the other ingredients.
All of these products are ECOCERT/COSMOS certified, which means independent third-party verification that the aloe vera raw material is actually organically grown and processed without harmful chemicals — a quality factor that affects how much of the bioactive polysaccharides are preserved in the finished product.
What This Means in Practice
Two things can be true at once: the research on oral aloe vera supplements against skin ageing is weak, while the mechanism behind how acemannan directly affects skin cells is more solidly documented than it has been in a long time. This is the kind of nuanced picture that rarely finds room in either product marketing or sceptical pushback against "trend ingredients."
There are still limitations worth remembering. The study was carried out on cell culture, not on whole skin or in a clinical trial format with measurable results on real users over time. That means the results are biologically promising and mechanistically well-founded, but they don't amount to proof that a finished cream or serum delivers a specific, measurable improvement for you as a consumer. That's the difference between "we now understand better why this might work" and "it's proven to work for you."
What SKINØ takes from this kind of research is confirmation of a formulation choice made on exactly that logic: an active base that does more than simply carry the other ingredients to the skin, rather than a word on the front of the package that isn't backed up by what's actually in the bottle.